Tuberculosis, often abbreviated as TB, is a complex infectious disease that has shaped human health and societies for centuries. Despite monumental progress in medical science, TB remains one of the world’s top 10 causes of death and the leading cause from a single infectious agent, surpassing HIV/AIDS. Every year, millions are diagnosed and affected by tuberculosis, making it a persistent global health challenge demanding our collective attention. With the right awareness and resources, however, TB is both preventable and curable, and understanding what TB is forms the bedrock of all prevention and treatment efforts.

TB is caused by the bacterium Mycobacterium tuberculosis, a slow-growing organism discovered in 1882 by Robert Koch—a milestone that redefined the trajectory of modern medicine. The bacterium is transmitted through the air whenever a person with active pulmonary TB coughs, sneezes, speaks, or even sings. Unlike many infectious agents, TB can remain dormant in the human body for years, making it a uniquely elusive foe. Only a fraction of those infected with the bacteria (approximately 5–10%) will go on to develop active, symptomatic tuberculosis in their lifetime, yet the burden is substantial: According to World Health Organization (WHO) 2023 statistics, about 10.6 million people fell ill with TB in 2021, and a staggering 1.6 million people died from the disease that year.

The history of TB stretches back millennia—skeletal remains from Egyptian mummies show signs of spinal tuberculosis, also called Pott’s disease, offering testimony to TB’s ancient existence. During the industrial revolution in the 18th and 19th centuries, TB (then referred to as “consumption”) devastated populations in crowded cities. Despite today’s advanced antibiotics, high-burden countries in Asia and Africa continue to grapple with high rates of TB related to factors such as HIV/AIDS incidence, poverty, emerging drug-resistant TB strains, and delayed access to healthcare.

How Tuberculosis Is Transmitted

Understanding the transmission of TB is essential for prevention. Mycobacterium tuberculosis primarily spreads via airborne droplets. When a person with active TB disease in their lungs coughs, sneezes, or spits, they expel microscopic droplets harboring TB bacilli into the air. These infectious droplets can linger in poorly ventilated spaces for hours, which means individuals sharing airspace with an infectious person are at significant risk. Nonetheless, TB is not spread by touching surfaces, sharing cups, or embracing an infected individual, distinguishing it from many other respiratory infections like influenza or the common cold.

The process from first contact to disease development is often long and complex. Many who inhale M. tuberculosis become infected but do not immediately develop symptoms—this is what we call latent TB infection (LTBI). However, if the immune system becomes weakened, either through another illness like HIV, old age, diabetes, or malnutrition, latent TB can “reactivate” and progress to active TB disease. This latent-to-active shift is responsible for much of the ongoing TB epidemic, especially in vulnerable populations. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 13 million people in the United States alone are estimated to have latent TB infection.

Types of Tuberculosis: Active vs. Latent

One of the most unique features of TB is its ability to manifest in two distinct forms: latent TB infection and active TB disease. Most commonly, TB attacks the lungs—a form called pulmonary TB. But it can also affect nearly every other organ, including lymph nodes, kidneys, bones, and even the central nervous system (termed extrapulmonary TB). This broad clinical spectrum underscores the importance of accurate diagnosis and tailored treatment.

In latent TB, the individual harbors the bacteria, but the immune system contains the infection. There are no symptoms, and chest X-rays are typically normal. Crucially, individuals with latent TB cannot transmit the bacteria to others. This explains why population-based TB control programs focus not only on treating active cases but also on identifying and treating those with latent infection in high-risk environments—such as within households of active TB patients or among people living with HIV.

Active TB, on the other hand, signifies the immune system has failed to contain the bacteria, allowing replication and spread. Symptoms vary depending on which organ is affected, but pulmonary TB typically presents with a cough lasting more than three weeks, sometimes with blood-tinged sputum, weight loss, night sweats, fever, and fatigue. Untreated, active TB can be fatal, and individuals with active pulmonary disease can infect 5–15 other people each year if not appropriately managed. Globally, the risk of progression from latent to active TB is estimated at about 10% over a lifetime, but for those with compromised immunity, this risk can be as high as 10% per year.

Tuberculosis Symptoms and Presentation

TB’s clinical presentation is famously variable, earning it the moniker “the great imitator.” The primary manifestation, pulmonary TB, remains the most common and contagious. Symptoms classically include a persistent, sometimes productive cough, hemoptysis (coughing up blood), chest pain, low-grade fevers, drenching night sweats, fatigue, and unexplained weight loss. These classic symptoms may evolve slowly, so much so that patients may endure symptoms for weeks to months before seeking care, inadvertently transmitting the infection to others during this period.

Extrapulmonary TB, affecting organs outside the lungs, can present differently based on the affected site. TB of the lymph nodes (scrofula) typically results in non-tender, enlarged lymph nodes in the neck; TB of the bones and joints can cause back pain or joint swelling; and TB meningitis is an especially severe manifestation associated with headaches, confusion, and neurological deficits. In immunocompromised patients, particularly those with HIV/AIDS, TB often presents in atypical or disseminated forms, complicating diagnosis and management further. The variable symptomatology means that maintaining a high degree of suspicion is necessary, especially in areas or populations at elevated risk.

Risk Factors and Populations at Risk

While anyone can develop TB, certain populations face a dramatically increased risk. Immunocompromised adults, especially those living with HIV, are at the forefront; HIV infection is the single most powerful risk factor for the progression of latent TB to active disease. Indeed, according to the WHO, around 9% of TB cases worldwide are among people living with HIV. Close contacts of people with infectious TB, individuals with chronic kidney disease, silicosis, diabetes mellitus, or who are undergoing immunosuppressive therapies (such as steroids or biologics), also have a higher susceptibility.

Socioeconomic factors play a substantial role. High population density, malnutrition, poverty, substance abuse, incarceration, and homelessness are strongly linked to increased rates of TB transmission and poor outcomes. Notably, about 95% of TB deaths occur in low- and middle-income countries, highlighting the need for social and economic interventions alongside medical treatment.

Pediatric TB presents a unique challenge, as children often develop severe, disseminated forms such as TB meningitis or miliary TB. Screening and early intervention in families or communities with active cases are thus critical for child health. Likewise, elderly adults face increased risk due to waning immunity, often complicated by other comorbid conditions.

Diagnosis of Tuberculosis

Diagnosing TB is not always straightforward. Early suspicion is vital, especially in high-risk individuals or those with suggestive symptoms. Often, the first diagnostic tools are the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs), both of which can detect latent TB infection. These tests, however, do not differentiate between active and latent TB, and false positives can occur, particularly if an individual has received the Bacille Calmette–Guérin (BCG) vaccine, which is common in TB-endemic countries.

For suspected active pulmonary TB, sputum analysis remains the gold standard. Microscopy for acid-fast bacilli (AFB), nucleic acid amplification tests (such as Xpert MTB/RIF), and culture of M. tuberculosis are crucial. Sputum culture not only confirms the diagnosis but also allows for drug susceptibility testing, essential for identifying drug-resistant strains. In extrapulmonary or pediatric cases, diagnosis may rely more heavily on imaging—like chest X-rays or CT scans—and tissue biopsies, since collecting sputum samples is often impractical.

Increasingly, rapid molecular diagnostics are shrinking the time to detection and resistance profiling. As these tools become more accessible, especially in resource-limited settings, early detection and timely treatment are becoming more achievable goals. However, challenges in sample collection, cost, and laboratory infrastructure persist, especially in rural regions or areas with limited healthcare access.

Drug-resistant Tuberculosis: A Growing Threat

One of the most alarming facets of TB’s continued dominance is the rise of drug-resistant strains. Multidrug-resistant TB (MDR-TB) is defined as TB that does not respond to at least isoniazid and rifampin, the two most potent anti-TB drugs. Even more concerning is extensively drug-resistant TB (XDR-TB), which is resistant to isoniazid, rifampin, any fluoroquinolone, and at least one of the injectable second-line drugs. According to the WHO, almost half a million people worldwide developed MDR-TB in 2021—a number that continues to grow annually.

Drug-resistant TB poses significant treatment challenges. Courses are lengthy (often 18–24 months), expensive, and fraught with side effects. Cure rates are lower than for drug-susceptible TB, and case fatality rates are substantially higher. The emergence of resistance is often driven by incomplete or inappropriate therapy, challenges in drug supply, and patient non-adherence. Tackling MDR- and XDR-TB requires a combination of robust public health policies, new antibiotics, and support for the patients enduring these long, complex regimens.

Tuberculosis Treatment

The discovery of effective antibiotics in the mid-20th century transformed TB from a death sentence into a curable disease. Standard therapy for drug-susceptible TB consists of a 6-month regimen of multiple antibiotics, usually isoniazid, rifampin, pyrazinamide, and ethambutol for the first two months, followed by isoniazid and rifampin for the remaining four months. This multi-drug approach is designed both to kill bacteria and to prevent the emergence of drug resistance.

Treatment for drug-resistant TB is considerably more complex, requiring a longer duration and a combination of second-line drugs, many of which are less effective and more toxic than the first-line agents. Directly Observed Therapy (DOT), where a healthcare provider administers each dose, is strongly encouraged for ensuring adherence and reducing relapse and resistance rates. A patient’s journey through TB therapy can be daunting: side effects, the stigma of the disease, and financial or social barriers often complicate adherence. Accordingly, social and psychological support is now recognized as a vital component of effective TB treatment programs.

For those concerned about cost, it is important to note that in most countries with advanced TB control programs, the medications for TB are provided at no charge to the patient, thanks to national and international funding. This is essential for limiting the spread and ensuring that barriers to access do not hinder public health efforts.

Preventing Tuberculosis

Tuberculosis is, at its core, a preventable disease. The BCG vaccine, first developed in 1921, is administered routinely in many countries with high TB incidence, especially to protect children from severe TB forms like meningitis and miliary TB. However, BCG offers only limited protection against the most common form—pulmonary TB in adults—hence the ongoing search for more effective vaccines.

Beyond vaccination, public health strategies focus on breaking the chain of transmission. Key interventions include rapid identification and treatment of infectious cases, contact tracing, testing, and treatment of latent TB (especially in high-risk groups), and improving living conditions and ventilation in congregate settings. Infection control in healthcare facilities, prisons, and shelters is particularly vital, where outbreaks can be swiftly amplified. Education—both of the public and healthcare providers—is crucial to diminish stigma, encourage prompt care-seeking, and facilitate community engagement in TB control.

Emerging strategies include increased use of preventive therapy (such as isoniazid preventive therapy, especially in people with HIV), development and rollout of improved diagnostic tools, and the pursuit of new generation vaccines with better efficacy and broader protection.

Tuberculosis in the Global Context

TB is not distributed evenly across the world. More than 80% of all TB cases occur in just 30 countries, with India, China, Indonesia, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa accounting for the majority of the global burden. The interconnectedness of TB and HIV remains a pressing challenge, with co-infected individuals facing far higher rates of morbidity and mortality. In the context of pandemics and other healthcare disruptions—such as the COVID-19 pandemic—TB case detection and treatment completion rates have suffered, reversing years of steady progress in TB control. The World Health Organization has described TB as a disease of poverty, highlighting the bidirectional relationship between poor health outcomes and economic instability.

Global efforts to combat TB are coordinated through initiatives such as the WHO’s End TB Strategy, the Stop TB Partnership, and regional public health collaborations. Progress is being made: since 2000, an estimated 74 million lives have been saved through TB prevention, diagnosis, and treatment. Yet the pathway to TB elimination remains challenging. Increased funding, political commitment, improved social support systems, and research innovation are all necessary to break down what remains one of humanity’s oldest scourges.

The importance of research cannot be overstated. In recent years, advances in genomics, rapid diagnostics, new antibiotics, and vaccine candidates have offered renewed hope. The implementation of short-course therapy for latent TB, targeted public health interventions, and novel delivery systems for care are ushering in a new era for TB control. Engagement with communities, addressing social determinants of health, and fostering partnerships across sectors are all vital if we are to achieve the global goal of eliminating TB as a public health problem by 2035.

Final Thoughts on Tuberculosis

Tuberculosis remains a global tragedy and a scientific challenge, but it is also a story of resilience and progress. Effective prevention, timely diagnosis, and compassionate, evidence-based treatment can save millions of lives each year. By deepening our understanding of TB—its causes, risk factors, diagnosis, and treatments—we can dismantle stigma and champion effective action, both within our own communities and on the world stage. If you suspect you or someone you know may have been exposed to TB, do not delay seeking medical advice; early intervention truly saves lives.

For more detailed and updated information on tuberculosis, consult reputable sources such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).

Join Our Health Newsletter for Expert Insights on TB and Other Crucial Health Topics